Marker Therapeutics (NASDAQ:MRKR) Trading Down 7.5% – What’s Next?

Marker Therapeutics, Inc. (NASDAQ:MRKR)’s share price dropped 7.5% during mid-day trading on Friday . The stock traded as low as $2.46 and last traded at $2.46. Approximately 48,743 shares changed hands during mid-day trading, an increase of 18% from the average daily volume of 41,268 shares. The stock had previously closed at $2.66.

Analyst Ratings Changes

Separately, LADENBURG THALM/SH SH lifted their price target on shares of Marker Therapeutics from $11.00 to $19.00 and gave the stock a “buy” rating in a research note on Monday, October 21st.

Marker Therapeutics Stock Down 7.5 %

The firm has a fifty day moving average price of $3.38 and a two-hundred day moving average price of $3.66.

Insider Buying and Selling at Marker Therapeutics

In related news, major shareholder Enterprise Associates 16 New purchased 554,250 shares of the firm’s stock in a transaction dated Monday, December 23rd. The stock was purchased at an average price of $3.20 per share, with a total value of $1,773,600.00. Following the completion of the purchase, the insider now owns 1,625,678 shares of the company’s stock, valued at approximately $5,202,169.60. The trade was a 51.73 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Steve Elms acquired 11,085 shares of the company’s stock in a transaction that occurred on Monday, December 23rd. The stock was purchased at an average cost of $3.20 per share, for a total transaction of $35,472.00. Following the purchase, the director now owns 325,370 shares of the company’s stock, valued at $1,041,184. This represents a 3.53 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 17.35% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Marker Therapeutics

A hedge fund recently bought a new stake in Marker Therapeutics stock. Invst LLC acquired a new stake in Marker Therapeutics, Inc. (NASDAQ:MRKR) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 20,000 shares of the company’s stock, valued at approximately $56,000. Invst LLC owned approximately 0.22% of Marker Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 22.39% of the company’s stock.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.